Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

BACKGROUND: Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment options for moderate-to-severe disease are limited. Ustekinumab is an IL-12/IL-23p40 antagonist that suppresses Th1, Th17 and Th22 activation, commonly used for psoriasis patients. OBJECTIVE: We sought to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Exp Dermatol
Auteurs principaux: Khattri, Saakshi, Brunner, Patrick M., Garcet, Sandra, Finney, Robert, Cohen, Steven R., Oliva, Margeaux, Dutt, Riana, Fuentes-Duculan, Judilyn, Zheng, Xiuzhong, Li, Xuan, Bonifacio, Kathleen M., Kunjravia, Norma, Coats, Israel, Cueto, Inna, Gilleaudeau, Patricia, Sullivan-Whalen, Mary, Suárez-Fariñas, Mayte, Krueger, James G., Guttman-Yassky, Emma
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5502835/
https://ncbi.nlm.nih.gov/pubmed/27304428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/exd.13112
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires